Arrowhead Pharmaceuticals, Inc. (ARWR) is a Healthcare stock trading at $87.14 (as of 2026-08-21), with a market capitalization of $12.31B. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
Insufficient source information was provided from Signals.AI’s SEC 10‑K Item 1 Business section to produce a fact-based description under the stated rules.
Understand Arrowhead Pharmaceuticals, Inc.: how it makes money
Arrowhead Pharmaceuticals develops RNA interference (RNAi) medicines for intractable diseases, and earns revenue largely through collaboration and licensing arrangements (including milestone, ongoing consideration recognition, and cost reimbursement components) tied to partner programs.
The company’s near-term revenue profile is driven by partner collaboration accounting (Sarepta license and collaboration components), while the provided Redemptilo-related derived net sales figure is shown as zero.
Business quality (Weak): Clear clinical pipeline across multiple RNAi candidates, but profitability is weak (operating margin is deeply negative) and the revenue mix shown is partnership-driven rather than product-sales-driven.
Bull case
Multiple late-stage pipeline efforts are underway, including ARO-APOC3 in phase 2b and one phase 3 clinical trial, and ARO-AAT in phase II for liver diseases linked to alpha-1 antitrypsin deficiency: The pipeline breadth increases optionality if clinical programs progress.
Clinical program execution is tracked with enrollment metrics (for example, SHASTA III and SHASTA IV enrollment, and MIRA3 enrollment): Enrollment progress can be an early indicator of how quickly potential pivotal data may emerge.
Redemptilo utilization is being monitored via prescription-related metrics, including average new weekly written prescriptions and the share of prescriptions for APOC3-Naive patients: These metrics help investors gauge near-term market traction and patient targeting.
Bear case
Operating performance is poor, with operating margin shown as -191.6%: This highlights heavy spending relative to revenue, increasing the importance of successful clinical and commercial outcomes.
Revenue components provided emphasize collaborations and partner-related arrangements (for example, Sarepta license and collaboration revenue and ongoing recognition of initial Sarepta consideration): If partner economics change or milestone timing shifts, reported revenue could be volatile.
The company’s pipeline programs are in clinical stages that range from phase 1/2a to phase 2b and phase 3, which implies ongoing uncertainty in trial outcomes: Clinical risk remains until trial results support continued development and potential regulatory pathways.